Parsons Capital Management Inc. RI reduced its stake in Iqvia Holdings Inc (NYSE:IQV) by 4.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,799 shares of the medical research company’s stock after selling 911 shares during the quarter. Parsons Capital Management Inc. RI’s holdings in Iqvia were worth $2,864,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. C J Advisory Inc purchased a new stake in shares of Iqvia in the first quarter valued at $27,000. Baystate Wealth Management LLC purchased a new stake in shares of Iqvia in the first quarter valued at $27,000. CWM LLC lifted its position in shares of Iqvia by 63.4% in the second quarter. CWM LLC now owns 165 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 64 shares in the last quarter. Parkside Financial Bank & Trust lifted its position in shares of Iqvia by 140.2% in the first quarter. Parkside Financial Bank & Trust now owns 209 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 122 shares in the last quarter. Finally, GWM Advisors LLC lifted its position in shares of Iqvia by 306.7% in the first quarter. GWM Advisors LLC now owns 20,403 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 15,386 shares in the last quarter. Institutional investors and hedge funds own 92.29% of the company’s stock.

Several brokerages have recently issued reports on IQV. Credit Suisse Group upped their price objective on Iqvia from $165.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Zacks Investment Research upgraded Iqvia from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. Morgan Stanley upped their price objective on Iqvia from $156.00 to $170.00 and gave the company an “overweight” rating in a research report on Wednesday, June 19th. Svb Leerink began coverage on Iqvia in a research report on Tuesday, May 28th. They issued an “outperform” rating and a $160.00 price objective on the stock. Finally, SunTrust Banks upped their price objective on Iqvia from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Three equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $161.13.

NYSE IQV traded up $2.07 during trading hours on Thursday, hitting $153.28. 37,099 shares of the company’s stock were exchanged, compared to its average volume of 1,093,367. The stock has a 50 day simple moving average of $157.88. Iqvia Holdings Inc has a 12-month low of $104.90 and a 12-month high of $164.13. The firm has a market capitalization of $30.44 billion, a price-to-earnings ratio of 29.89, a P/E/G ratio of 1.89 and a beta of 0.88. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 1.72.

Iqvia (NYSE:IQV) last released its earnings results on Wednesday, July 24th. The medical research company reported $1.39 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.38 by $0.01. Iqvia had a return on equity of 15.95% and a net margin of 2.31%. The firm had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.70 billion. During the same period in the prior year, the business posted $1.29 earnings per share. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. On average, research analysts anticipate that Iqvia Holdings Inc will post 5.86 EPS for the current fiscal year.

In other news, insider Ari Bousbib sold 96,000 shares of the firm’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $160.00, for a total value of $15,360,000.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Kevin C. Knightly sold 6,945 shares of the firm’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $158.53, for a total value of $1,100,990.85. The disclosure for this sale can be found here. Insiders have sold 198,945 shares of company stock worth $30,860,991 over the last quarter. 6.00% of the stock is currently owned by company insiders.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Article: Do stock splits help investors?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.